Last reviewed · How we verify
Intravenous Diltiazem
Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits calcium influx into cardiac and vascular smooth muscle cells, reducing heart rate and blood pressure.
Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits calcium influx into cardiac and vascular smooth muscle cells, reducing heart rate and blood pressure. Used for Supraventricular tachycardia (acute management), Atrial fibrillation with rapid ventricular response (acute management), Hypertensive crisis.
At a glance
| Generic name | Intravenous Diltiazem |
|---|---|
| Also known as | Diltiazem nondihydropyridine calcium channel blocker |
| Sponsor | Oman Medical Speciality Board |
| Drug class | Non-dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Diltiazem blocks L-type calcium channels in the sinoatrial and atrioventricular nodes, slowing conduction velocity and increasing refractoriness. This results in negative chronotropic and dromotropic effects, reducing heart rate and contractility while also causing vasodilation of coronary and peripheral arteries. The intravenous formulation provides rapid onset for acute management of supraventricular arrhythmias and hypertensive episodes.
Approved indications
- Supraventricular tachycardia (acute management)
- Atrial fibrillation with rapid ventricular response (acute management)
- Hypertensive crisis
Common side effects
- Hypotension
- Bradycardia
- Dizziness
- Headache
- Flushing
- Asthenia/fatigue
- Atrioventricular block
Key clinical trials
- Adenosine vs. Diltiazem (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate. (PHASE3)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation (NA)
- Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial (PHASE4)
- Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Diltiazem CI brief — competitive landscape report
- Intravenous Diltiazem updates RSS · CI watch RSS
- Oman Medical Speciality Board portfolio CI